|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400092870 |
|
最近更新日期: Date of Last Refreshed on: |
2024-11-25 17:03:28 |
|
注册时间: Date of Registration: |
2024-11-25 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
基于斑点追踪超声心动图评估脓毒症患者全心功能状态及其与预后的关系: 一项前瞻性观察性队列研究 |
|
Public title: |
Assessment of global cardiac function in patients with sepsis based on speckle tracking echocardiography and its relationship with prognosis: a prospective observational cohort study |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于斑点追踪超声心动图评估脓毒症患者全心功能状态及其与预后的关系: 一项前瞻性观察性队列研究 |
|
Scientific title: |
Assessment of global cardiac function in patients with sepsis based on speckle tracking echocardiography and its relationship with prognosis: a prospective observational cohort study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
王慧铭 |
研究负责人: |
司向 |
|
Applicant: |
Wang Huiming |
Study leader: |
Si Xiang |
|
申请注册联系人电话: Applicant telephone: |
+86 87755766 |
研究负责人电话:
Study leader's |
+86 87755766 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
wanghuiming2020@outlook.com |
研究负责人电子邮件: Study leader's E-mail: |
James_sixiang@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
广东省广州市越秀区中山二路58号 |
研究负责人通讯地址: |
广东省广州市越秀区中山二路58号 |
|
Applicant address: |
58 Zhongshan Second Road, Yuexiu District, Guangzhou, Guangdong |
Study leader's address: |
58 Zhongshan Second Road, Yuexiu District, Guangzhou, Guangdong |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
中山大学附属第一医院 |
||
|
Applicant's institution: |
The First Affiliated Hospital, Sun Yat-Sen University |
||
|
研究负责人所在单位: |
中山大学附属第一医院 |
||
|
Affiliation of the Leader: |
The First Affiliated Hospital, Sun Yat-Sen University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
伦审临[2024]173 号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中山大学附属第一医院临床科研和动物实验伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Clinical Research and Animal Experiments, the First Affiliated Hospital, Sun Yat-Sen University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-04-01 00:00:00 | ||
|
伦理委员会联系人: |
陈湛永 |
||
|
Contact Name of the ethic committee: |
Chen Zhanyong |
||
|
伦理委员会联系地址: |
广东省广州市越秀区中山二路58号 |
||
|
Contact Address of the ethic committee: |
58 Zhongshan Second Road, Yuexiu District, Guangzhou, Guangdong |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 20 8733 4871 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
中山大学附属第一医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The First Affiliated Hospital, Sun Yat-Sen University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
广东省广州市越秀区中山二路58号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
58 Zhongshan Second Road, Yuexiu District, Guangzhou, Guangdong |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
吴阶平基金会 |
||||||||||||||||||||||
|
Source(s) of funding: |
Wu Jieping Medical Foundation |
||||||||||||||||||||||
|
研究疾病: |
脓毒症心肌病 |
||||||||||||||||||||||
|
Target disease: |
Septic cardiomyopathy |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
(1)通过心脏斑点追踪超声心动图及传统心脏超声参数动态评估脓毒症患者的心功能状态,以阐明脓毒症心功能障碍的表现形式及其动态演变过程。 (2)通过聚类脓毒症患者的斑点追踪超声心动图及传统心脏超声参数的动态检查结果,比较各亚型脓毒症心功能障碍患者的临床特征,分析相关危险因素。 (3)通过单因素及多因素生存分析,阐明心脏各腔室应变参数的动态变化情况在脓毒症患者预后评估中的价值 |
||||||||||||||||||||||
|
Objectives of Study: |
(1) To dynamically evaluate the cardiac functional status of sepsis patients by cardiac speckle tracking echocardiography and traditional cardiac ultrasound parameters, so as to elucidate the manifestations and dynamic evolution of sepsis cardiac dysfunction. (2) The clinical characteristics of patients with cardiac dysfunction in sepsis subtypes were compared and the relevant risk factors were analyzed by speckle tracking echocardiography and dynamic examination results of traditional cardiac ultrasound parameters in patients with cluster sepsis. (3) Univariate and multivariate survival analysis were used to clarify the value of dynamic changes in cardiac strain parameters in the prognosis assessment of patients with sepsis |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
①年龄>=18 周岁; ②脓毒症或感染性休克患者。脓毒症及感染性休克的诊断标准参照 2016 年国际脓毒症指南sepsis3.0 标准,脓毒症定义为存在或疑似感染,SOFA评分在基线水平上升高>=2分。感染性休克定义为在脓毒症诊断明确的基础上,经充分液体复苏治疗后仍需使用血管活性药物维持 MAP≥65mmHg,且血乳酸水平>2mmol/L。 ③诊断脓毒症不超过24小时 |
||||||||||||||||||||||
|
Inclusion criteria |
(1) Age>=18 years old; (2) Patients with sepsis or septic shock. Sepsis and septic shock are diagnosed according to the 2016 International Sepsis Guidelines sepsis3.0, which is defined as the presence or suspicion of infection, and the SOFA score rises above baseline by >=2 points. Septic shock is defined as maintenance of MAP ≥65 mmHg with vasoactive medication and a blood lactate level of > 2 mmol/L despite adequate fluid resuscitation on the basis of a clear diagnosis of sepsis. (3) Diagnosis of sepsis should not be carried out within 24 hours |
||||||||||||||||||||||
|
排除标准: |
1、经超声心动图证实的缺血性心肌病、肥厚性心肌病、扩张性心肌病 2、近30天发生急性冠脉综合征或心力衰竭 3、中至重度心脏瓣膜病及瓣膜置换术后 4、妊娠状态 5、射血分数降低的慢性心力衰竭 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Ischemic cardiomyopathy, hypertrophic cardiomyopathy, dilated cardiomyopathy confirmed by echocardiography 2. Acute coronary syndrome or heart failure in recent 30 days 3. Moderate to severe valvular heart disease and after valve replacement 4. Pregnancy status 5. Chronic heart failure with reduced ejection fraction |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-12-01 00:00:00至 To 2025-07-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-12-01 00:00:00 至 To 2025-05-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
none |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
N/A |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
CRF表及临床试验公共管理平台ResMan (http://www.medresman.org.cn/login.aspx) |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF and ResMan (http://www.medresman.org.cn/login.aspx) |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |